KISSH Plastic Colloidal Gold Rapid Antigen Test Home Kit CE

SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) 5 Tests/Kit

Theory

The SARS-CoV-2 Antigen Test Kit (GICA) is a colloidal gold enhanced double antibody sandwich immunoassay for the qualitative determination of nucleocapsid (N) protein of SARS-CoV-2 virus in human nasal (anterior) swab.

SARS-CoV-2 antibody is immobilized in the test region on nitrocellulose membrane. If the specimen contains SARS-CoV-2 antigen, during the assay specimen is allowed to react with the colored conjugate (SARS-CoV-2 antibody-colloidal gold conjugate); the mixture then migrates chromatographically on the membrane by the capillary action. An SARS-CoV-2 positive specimen produces a distinct color band in the test region, formed by the specific antibody antigen colored conjugate complex "(Au-SARS-CoV-2-Ab)-(SARS-CoV-2-Ag)- (SARS-CoV-2-Ab)". Absence of this colored band in the test region suggests a negative result. A colored band always appears in the control region serving as procedural control regardless of the specimen contains SARS-CoV-2 or not.

.

Product specifications

Test procedure

1. Open your test kit and take out all the components.

2. Twist off the top of the buffer bottle, slowly dispense all of the buffer into the extraction tub.

3. Open and take out the swab

4. Carefully insert the swab into the nostril until you fell a slight resistance (about 1.5-2.5cm up your nose). Using gentle rotation, roll the swab firmly around the inside of the nostril, making 5 complete circles each nostril, and then slowly remove it while wiping.

5. Elution of samples from swabs

6.Open pouch and place the card on a clean, dry, flat surface

7. Apply 3 drops of extracted sample at a 90º angle to the specimen well of the test card.

8. Wait 15 minutes

9. Interpret the test results at 15~20 minutes.

Shenzhen Kisshealh Biotechnology Co., Ltd., located in the Pingshan District, Shenzhen, P.R. China. is a diagnostics company focused on the development and manufacture of IVD tests at the Point-of-Care with highly innovative proprietary technology.

We focused on the emerging markets of in vitro pathological diagnosis and immunodiagnosis. We developed, manufactured and successfully launched the in vitro immunodiagnosis platform for cancer and the POCT for infectious, genetic and chronic diseases.

<span style="color: rgb(33, 33, 33); text-transform: none; text-indent: 0px; letter-spacing: normal;" initial;"="" initial;="" 0px;="" normal;="" 255);="" 255,="" rgb(255,="" 2;="" !important;="" inline="" none;="" 600;="" 14px;="" sans-serif;="" arial,="" roboto,="" w3",="" gb="" sans="" "hiragino="" gb",="" hei",="" micro="" "wenquanyi="" sans",="" "droid="" arimo,="" freesans,="" yahei",="" "microsoft="" helvetica,="" grande",="" "lucida="" ui",="" segoe="">At Kissh we work every day to shape the future of in-vitro diagnostic testing. And our people are our best asset, the reason for our track record and our strength while we are moving forward. We live by our fundamental values and incorporate them in everything that we do. Our best asset is ‘Step Forward Every Second’